The civic record
Read. Follow. Verify.Idaho Establishes Two-Year Moratorium on Certain Human Gene Therapy Products for Minors and Pregnant Women
Last action · March 30, 2026: Recommitted to Health & Welfare
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Proposed
Idaho bans the administration of for infectious disease indications to individuals under eighteen years of age and pregnant women for a period of two years. The restriction applies regardless of whether the product is termed an immunization or vaccine, with specific exemptions for cancer treatment, genetic disorders, active clinical trials, and compassionate use.
Sets a two-year restriction on administering specific biologic and genetic products to minors and pregnant women, establishing legal penalties or prohibitions on providers while providing pathways for legislative exemption based on safety data.
- State legislatures have increasingly introduced bills addressing vaccine mandates, medical exemptions, and novel biotechnology products. context
Who It Would Have Affected
Groups the bill's text would have affected, as described in the record. Being affected is not a position for or against it.
Children under eighteen years of age
Minors are prohibited from being administered human gene therapy products for infectious disease indications during the two-year moratorium.
Pregnant women
Healthcare providers
Providers are barred from administering specified gene therapy products to protected groups unless an exemption applies.
Key Facts
- Establishes a two-year moratorium on administering human gene therapy products for any infectious disease indication to children under eighteen years of age, children in the womb, and pregnant women.
- Defines human gene therapy products to include nucleic acids, genetically modified microorganisms, engineered site-specific nucleases, and ex vivo genetically modified human cells.
- Exempts human gene therapy products utilized for the treatment or therapy of cancer or genetic disorders.
- Allows individual products to be exempted if the legislature determines safety data proves the product safe, proper informed consent procedures exist, and compensation for adverse outcomes is assured.
Show all 6 facts
- Exempts products that are part of a clinical trial covered under an active institutional review board protocol or provided under expanded access for serious or life-threatening conditions.
- Declares an emergency, putting the act into effect immediately upon its passage and approval.
Frequently Asked Questions
Who is affected by this moratorium?
Are there any exceptions for cancer or genetic disorders?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
This bill did not become law - Died at adjournment · in Senate committee.
Procedural history
4 actions- Mar 30, 2026Recommitted to Health & Welfare
- Mar 5, 2026Reported out of committee; to 14th Order for amendment
- Feb 27, 2026CommitteeReported Printed; referred to Health & Welfare
- Feb 26, 2026IntroducedIntroduced; read first time; referred to JR for Printing
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
State-Level Geographically Targeted Moratorium on Biologics
The bill implements an unusual state-level prohibition on specific medical product administrations tied to infectious disease indications.
Connected Entities
Sources
legislature.idaho.gov
Analysis Score
0–100- Significance20Lowered because this bill did not pass (its text scored 85)
- Controversy90Intensity of disagreement among stakeholders
- Entertainment10Compellingness for a non-policy-wonk reader
- Buzz75Current news / social attention level
Publisher tools